HURA — TuHURA Biosciences, Inc./NV
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1498382 ·
Last close
$1.40
Market Cap
$89.22M
52W High
$3.43
52W Low
$0.41
ADV30
460,485
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -5,660,761 | -6,409,585 | 36,243,594 | 1,894,351 | 17,290,070 |
| Jun 2026 | 0 | — | -8,763,284 | -9,223,298 | 31,746,253 | 995,977 | 13,245,793 |
| Mar 2026 | 0 | — | -7,529,899 | -7,536,598 | 29,704,779 | 6,298,127 | 6,514,898 |
| Dec 2025 | 0 | — | -4,380,165 | -6,761,316 | 27,353,156 | 3,619,949 | 6,420,828 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,689,118
Investing CF
$-213,674
Financing CF
$22,385,945
CapEx
$-219,235
Dividends Paid
$-8,356
Buybacks
—
EPS Diluted TTM
$-0.62
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-157,948,976
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-29,502,776
Pretax Income TTM
$-30,623,667
Interest Exp TTM
$1,120,891
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,289,239 | -30,051,977 | 27,353,156 | 6,420,828 | 20,932,328 | -27,629,150 |
| Dec 2024 | 0 | -17,151,525 | -21,682,306 | 19,966,684 | 5,372,708 | 14,593,976 | -14,728,138 |
| Dec 2023 | 0 | -13,170,156 | -29,316,826 | 4,361,791 | 5,920,537 | -1,558,746 | -11,950,856 |
| Dec 2022 | 0 | -9,718,934 | -9,367,513 | 15,196,608 | 2,892,667 | 12,303,941 | -7,508,259 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-30,623,667
OpCashFlow TTM
—
Assets (Latest)
$31,746,253
Forward EPS
$-0.62
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NKTX | Nkarta, Inc. | $89.53M | $1.25 | — |
| GNLX | GENELUX Corp | $90.49M | $2.00 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $86.96M | $5.80 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| DERM | Journey Medical Corp | $86.70M | $3.90 | — |
News headlines (Yahoo Finance, 1h cache)
TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-13 12:45 · Yahoo
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
2026-11-04 14:15 · Yahoo
HURA: First Look at IFx-2.0 Deep-Seated Tumors
2026-11-03 12:00 · Yahoo
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
2026-10-26 20:02 · Yahoo
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Ca
2026-10-26 11:30 · Yahoo
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
2026-10-13 11:45 · Yahoo
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
2026-10-05 11:45 · Yahoo
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related
2026-09-14 11:45 · Yahoo
HURA: Milestone Progression Over Next 12 Months
2026-08-26 09:12 · Yahoo
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
2026-08-14 15:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.